Related Experiment Video
Updated: Aug 10, 2026
07:32
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Developing Mixed Micelle Delivery Systems for Aromatase Inhibitors
Sheetal Vermani1, Palwinder Singh1, Varinder Kaur1
1Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India.
ACS Omega
|August 8, 2026
Summary
A novel nanodrug delivery system using Pluronics enhances the efficacy of compound 1-(a), a potent aromatase inhibitor, for breast cancer therapy. This formulation improves solubility and bioavailability, showing promising therapeutic potential with minimal toxicity.
Area of Science:
- Pharmaceutical Science
- Nanotechnology
- Oncology
Background:
- Aromatase is a key enzyme in estrogen synthesis and a therapeutic target for estrogen receptor-positive (ER+) breast cancer.
- Existing aromatase inhibitors have limitations including adverse side effects and poor pharmacokinetics, impacting treatment outcomes.
- Compound 1-(a) previously showed potent aromatase inhibition (IC50 = 54.0 nM) and tumor growth inhibition.
Purpose of the Study:
- To evaluate the pharmaceutical viability of compound 1-(a) by assessing its toxicity, bioavailability, and therapeutic efficacy.
- To develop and optimize a nanodrug delivery system to improve the solubility and pharmacokinetic profile of compound 1-(a).
- To investigate the in vitro and in vivo performance of the developed nanodrug formulation.
Main Methods:
- In vivo acute toxicity studies were conducted to assess the safety of compound 1-(a).
- A mixed micelle-based delivery system using Pluronics P123 and F127 was developed and optimized (2:1 formulation).
- The nanomicellar formulation's drug loading (8.8%), entrapment efficiency (80%), solubility, stability, cellular uptake (MCF-7, MDA-MB-231), and in vitro drug release were evaluated.
Main Results:
- Compound 1-(a) demonstrated safety in acute toxicity studies with no significant adverse effects.
- The optimized Pluronics-based micellar formulation significantly improved compound 1-(a)'s solubility, stability, and cellular uptake.
- The formulation exhibited sustained drug release characteristics across different pH conditions (1.2, 6.8, 7.4).
Conclusions:
- Pluronics P123 and F127 form an effective mixed micelle delivery system for the potent aromatase inhibitor compound 1-(a).
- The developed nanodrug formulation enhances the pharmaceutical properties and therapeutic potential of compound 1-(a) for breast cancer treatment.
- This study supports the use of Pluronics as a viable drug delivery strategy for potent aromatase inhibitors.
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:30Micelles
Micelle formation is an intricate process that hinges on the properties of amphiphilic or amphipathic molecules and the conditions of the system in which they are found. Amphiphilic molecules, which have both hydrophilic (water-attracting) and hydrophobic (water-repelling) parts, play a critical role in this process.In aqueous environments, these molecules arrange themselves such that their hydrophilic heads are turned towards the water phase, while their hydrophobic tails are oriented away...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...